SCHEMBL25181574

SCHEMBL25181574

CC(C)(C)OC(=O)N1CC(SCCO)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.54
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NAMPT P43490 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RECQL P46063 1/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ RORC P51449 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ PREP P48147 1/20 0.35
▸ EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25177622 0.88 NR1H2 (0.46) NR1H2USP2SMN1; SMN2MEN1ALDH1A1
SCHEMBL21640603 0.83 NR1H2 (0.53) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL15861680 0.80 NR1H2 (0.50) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL23579404 0.80 NR1H2 (0.54) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL21640265 0.78 NR1H2 (0.54) NR1H2USP2SMN1; SMN2NAMPTMEN1
Lithium Ion SCHEMBL21063466 0.78 NR1H2 (0.48) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL4184533 0.77 NR1H2 (0.53) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL16415111 0.77 NR1H2 (0.54) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL16415113 0.77 NR1H2 (0.54) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL16415112 0.77 NR1H2 (0.54) NR1H2USP2SMN1; SMN2NAMPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 — — US disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 — — US disclosed
EP-4426695-A1 KRAS G12C INHIBITORS Frontier Medicines Corporation (US) 2024-09-11 — — EP disclosed
WO-2023081840-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION (US) 2023-05-11 — — WO disclosed
WO-2023081840-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION (US) 2023-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12291539-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS NR1H2 2175/4885USP2 953/4885SMN1; SMN2 2757/4885
US-20250019387-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 2175/4885USP2 953/4885SMN1; SMN2 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback